Table 2. Patients' clinicopathological characteristics according to breast cancer phenotype.
| Parameters | Total (n = 709) (%) | Luminal A (n = 297) (%) | Luminal B (n = 168) (%) | HER-2 (n = 70) (%) | TNBC (n = 174) (%) | P-value |
| Age (yr, mean ±SD) | 49.7±10.9 | 50.5±10.5 | 48.4±10.0 | 52.4±10.0 | 48.2±12.5 | 0.011 |
| Histologic grade | <0.001 | |||||
| I | 119 (16.7) | 90 (30.3) | 19 (11.3) | 1 (1.4) | 7 (4.0) | |
| II | 360 (50.6) | 179 (60.3) | 92 (54.8) | 36 (51.4) | 53 (30.5) | |
| III | 232 (32.6) | 28 (9.4) | 57 (33.9) | 33 (47.1) | 114 (65.5) | |
| Tumor stage | 0.014 | |||||
| T1 | 346 (48.7) | 162 (54.5) | 86 (51.2) | 30 (42.9) | 66 (37.9) | |
| T2 | 350 (49.2) | 127 (42.8) | 80 (47.6) | 39 (55.7) | 104 (59.8) | |
| T3 | 15 (2.1) | 8 (2.7) | 2 (1.2) | 1 (1.4) | 4 (2.3) | |
| Nodal stage | 0.055 | |||||
| N0 | 420 (59.1) | 170 (57.2) | 92 (54.8) | 42 (60.0) | 115 (66.1) | |
| N1 | 188 (26.4) | 86 (29.0) | 43 (25.6) | 13 (18.6) | 45 (25.9) | |
| N2 | 64 (9.0) | 26 (8.8) | 18 (10.7) | 10 (14.3) | 10 (5.7) | |
| N3 | 39 (5.5) | 15 (5.1) | 15 (8.9) | 5 (7.1) | 4 (2.3) | |
| Estrogen receptor status | <0.001 | |||||
| Negative | 254 (35.7) | 5 (1.7) | 5 (3.0) | 70 (100.0) | 174 (100.0) | |
| Positive | 457 (64.3) | 292 (98.3) | 163 (97.0) | 0 (0.0) | 0 (0.0) | |
| Progesterone receptor status | <0.001 | |||||
| Negative | 339 (47.7) | 48 (16.2) | 48 (28.6) | 69 (98.6) | 174 (100.0) | |
| Positive | 372 (52.3) | 249 (83.8) | 120 (71.4) | 1 (1.4) | 0 (0.0) | |
| HER-2 status | <0.001 | |||||
| 0 | 262 (36.8) | 107 (36.0) | 24 (14.3) | 0 (0.0) | 129 (74.1) | |
| 1+ | 184 (25.9) | 119 (40.1) | 33 (19.6) | 0 (0.0) | 32 (18.4) | |
| 2+ | 141 (19.8) | 71 (23.9) | 41 (24.4) | 16 (22.9) | 13 (7.5) | |
| 3+ | 124 (17.4) | 0 (0.0) | 70 (41.7) | 54 (77.1) | 0 (0.0) | |
| Ki-67 LI (%, mean ±SD) | 17.4±18.4 | 4.7±3.7 | 19.5±12.4 | 19.7±12.9 | 36.1±22.9 | <0.001 |
| Tumor recurrence | 63 (8.9) | 14 (4.7) | 13 (7.7) | 12 (17.1) | 24 (13.8) | 0.001 |
| Patients' death | 59 (8.3) | 12 (4.0) | 12 (7.1) | 12 (17.1) | 23 (13.2) | <0.001 |
| Duration of clinical follow-up (months, mean ±SD) | 69.9±31.2 | 72.7±29.6 | 70.1±30.1 | 64.9±34.1 | 67.0±33.5 | 0.127 |
TNBC, triple negative breast cancer.